274 related articles for article (PubMed ID: 25123357)
1. Re-irradiation of recurrent glioblastoma multiforme using 11C-methionine PET/CT/MRI image fusion for hypofractionated stereotactic radiotherapy by intensity modulated radiation therapy.
Miwa K; Matsuo M; Ogawa S; Shinoda J; Yokoyama K; Yamada J; Yano H; Iwama T
Radiat Oncol; 2014 Aug; 9():181. PubMed ID: 25123357
[TBL] [Abstract][Full Text] [Related]
2. Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy.
Grosu AL; Weber WA; Franz M; Stärk S; Piert M; Thamm R; Gumprecht H; Schwaiger M; Molls M; Nieder C
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):511-9. PubMed ID: 16168843
[TBL] [Abstract][Full Text] [Related]
3. Hypofractionated high-dose irradiation with positron emission tomography data for the treatment of glioblastoma multiforme.
Miwa K; Matsuo M; Ogawa S; Shinoda J; Asano Y; Ito T; Yokoyama K; Yamada J; Yano H; Iwama T
Biomed Res Int; 2014; 2014():407026. PubMed ID: 24977151
[TBL] [Abstract][Full Text] [Related]
4. Impact of [11C]methionine positron emission tomography for target definition of glioblastoma multiforme in radiation therapy planning.
Matsuo M; Miwa K; Tanaka O; Shinoda J; Nishibori H; Tsuge Y; Yano H; Iwama T; Hayashi S; Hoshi H; Yamada J; Kanematsu M; Aoyama H
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):83-9. PubMed ID: 21095072
[TBL] [Abstract][Full Text] [Related]
5. Amino-acid PET versus MRI guided re-irradiation in patients with recurrent glioblastoma multiforme (GLIAA) - protocol of a randomized phase II trial (NOA 10/ARO 2013-1).
Oehlke O; Mix M; Graf E; Schimek-Jasch T; Nestle U; Götz I; Schneider-Fuchs S; Weyerbrock A; Mader I; Baumert BG; Short SC; Meyer PT; Weber WA; Grosu AL
BMC Cancer; 2016 Oct; 16(1):769. PubMed ID: 27716184
[TBL] [Abstract][Full Text] [Related]
6. Phase I study of hypofractionated intensity modulated radiation therapy with concurrent and adjuvant temozolomide in patients with glioblastoma multiforme.
Jastaniyah N; Murtha A; Pervez N; Le D; Roa W; Patel S; Mackenzie M; Fulton D; Field C; Ghosh S; Fallone G; Abdulkarim B
Radiat Oncol; 2013 Feb; 8():38. PubMed ID: 23425509
[TBL] [Abstract][Full Text] [Related]
7. Impact of 11C-methionine positron emission tomography/computed tomography on radiation therapy planning and prognosis in patients with primary brain tumors.
Schinkelshoek M; Lopci E; Clerici E; Alongi F; Mancosu P; Rodari M; Navarria P; van der Hiel B; Scorsetti M; Chiti A
Tumori; 2014; 100(6):636-44. PubMed ID: 25688497
[TBL] [Abstract][Full Text] [Related]
8. Clinical value of [¹¹C]methionine PET for stereotactic radiation therapy with intensity modulated radiation therapy to metastatic brain tumors.
Miwa K; Matsuo M; Shinoda J; Aki T; Yonezawa S; Ito T; Asano Y; Yamada M; Yokoyama K; Yamada J; Yano H; Iwama T
Int J Radiat Oncol Biol Phys; 2012 Dec; 84(5):1139-44. PubMed ID: 22520479
[TBL] [Abstract][Full Text] [Related]
9. Simultaneous integrated boost technique by helical tomotherapy for the treatment of glioblastoma multiforme with 11C-methionine PET: report of three cases.
Miwa K; Matsuo M; Shinoda J; Oka N; Kato T; Okumura A; Ueda T; Yokoyama K; Yamada J; Yano H; Yoshimura S; Iwama T
J Neurooncol; 2008 May; 87(3):333-9. PubMed ID: 18217211
[TBL] [Abstract][Full Text] [Related]
10. Integrated-boost IMRT or 3-D-CRT using FET-PET based auto-contoured target volume delineation for glioblastoma multiforme--a dosimetric comparison.
Piroth MD; Pinkawa M; Holy R; Stoffels G; Demirel C; Attieh C; Kaiser HJ; Langen KJ; Eble MJ
Radiat Oncol; 2009 Nov; 4():57. PubMed ID: 19930657
[TBL] [Abstract][Full Text] [Related]
11. The use of hypofractionated intensity-modulated irradiation in the treatment of glioblastoma multiforme: preliminary results of a prospective trial.
Sultanem K; Patrocinio H; Lambert C; Corns R; Leblanc R; Parker W; Shenouda G; Souhami L
Int J Radiat Oncol Biol Phys; 2004 Jan; 58(1):247-52. PubMed ID: 14697445
[TBL] [Abstract][Full Text] [Related]
12. High-grade glioma radiation therapy target volumes and patterns of failure obtained from magnetic resonance imaging and 18F-FDOPA positron emission tomography delineations from multiple observers.
Kosztyla R; Chan EK; Hsu F; Wilson D; Ma R; Cheung A; Zhang S; Moiseenko V; Benard F; Nichol A
Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):1100-6. PubMed ID: 24161427
[TBL] [Abstract][Full Text] [Related]
13. Association of 11C-methionine PET uptake with site of failure after concurrent temozolomide and radiation for primary glioblastoma multiforme.
Lee IH; Piert M; Gomez-Hassan D; Junck L; Rogers L; Hayman J; Ten Haken RK; Lawrence TS; Cao Y; Tsien C
Int J Radiat Oncol Biol Phys; 2009 Feb; 73(2):479-85. PubMed ID: 18834673
[TBL] [Abstract][Full Text] [Related]
14. Integrated boost IMRT with FET-PET-adapted local dose escalation in glioblastomas. Results of a prospective phase II study.
Piroth MD; Pinkawa M; Holy R; Klotz J; Schaar S; Stoffels G; Galldiks N; Coenen HH; Kaiser HJ; Langen KJ; Eble MJ
Strahlenther Onkol; 2012 Apr; 188(4):334-9. PubMed ID: 22349712
[TBL] [Abstract][Full Text] [Related]
15. Phase I trial of hypofractionated intensity-modulated radiotherapy with temozolomide chemotherapy for patients with newly diagnosed glioblastoma multiforme.
Chen C; Damek D; Gaspar LE; Waziri A; Lillehei K; Kleinschmidt-DeMasters BK; Robischon M; Stuhr K; Rusthoven KE; Kavanagh BD
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):1066-74. PubMed ID: 20932651
[TBL] [Abstract][Full Text] [Related]
16. Concurrent temozolomide and dose-escalated intensity-modulated radiation therapy in newly diagnosed glioblastoma.
Tsien CI; Brown D; Normolle D; Schipper M; Piert M; Junck L; Heth J; Gomez-Hassan D; Ten Haken RK; Chenevert T; Cao Y; Lawrence T
Clin Cancer Res; 2012 Jan; 18(1):273-9. PubMed ID: 22065084
[TBL] [Abstract][Full Text] [Related]
17. Analysis of FET-PET imaging for target volume definition in patients with gliomas treated with conformal radiotherapy.
Rieken S; Habermehl D; Giesel FL; Hoffmann C; Burger U; Rief H; Welzel T; Haberkorn U; Debus J; Combs SE
Radiother Oncol; 2013 Dec; 109(3):487-92. PubMed ID: 23953407
[TBL] [Abstract][Full Text] [Related]
18. Relapse patterns after radiochemotherapy of glioblastoma with FET PET-guided boost irradiation and simulation to optimize radiation target volume.
Piroth MD; Galldiks N; Pinkawa M; Holy R; Stoffels G; Ermert J; Mottaghy FM; Shah NJ; Langen KJ; Eble MJ
Radiat Oncol; 2016 Jun; 11():87. PubMed ID: 27342976
[TBL] [Abstract][Full Text] [Related]
19. Phase 2 trial of hypofractionated high-dose intensity modulated radiation therapy with concurrent and adjuvant temozolomide for newly diagnosed glioblastoma.
Iuchi T; Hatano K; Kodama T; Sakaida T; Yokoi S; Kawasaki K; Hasegawa Y; Hara R
Int J Radiat Oncol Biol Phys; 2014 Mar; 88(4):793-800. PubMed ID: 24495592
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of moderately hypofractionated simultaneous integrated boost intensity-modulated radiotherapy combined with temozolomide for the postoperative treatment of glioblastoma multiforme: a single-institution experience.
Zhong L; Chen L; Lv S; Li Q; Chen G; Luo W; Zhou P; Li G
Radiat Oncol; 2019 Jun; 14(1):104. PubMed ID: 31196126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
